A Phase 1/2 interventional study of End-expiratory lung volume optimization maneuver with PEEP titration and Standard Care (in control arm) in Congenital Heart Disease, Cardiopulmonary Bypass and Cardiac Surgery, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Charite University, Berlin, Germany · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Heart Defects, Congenital with a site in Germany — 15 open to participants now, 15 under way, none of them phase 3. Heart Defects, Congenital · Germany.
Among the 38 studies in Heart Defects, Congenital with a site in Germany, this one is the 9th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2025, is one of 2 in phase 1/2, reaches primary completion later than 4 of the 14 other live ones, and was the 33rd registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →15 of the 38 studies in Heart Defects, Congenital with a site in Germany are open now. Recruiting first, the newest first:
Alexandra Miriam Kiess · Sites in Germany
Ages 6–18
University Hospital Tuebingen · Sites in Germany
Fondation Hôpital Saint-Joseph · Sites in Germany, Denmark, Egypt and 14 more countries
Ages 1 mo+
Deutsches Herzzentrum Muenchen · Sites in Germany
Ages 8–14
University Hospital, Bordeaux · Sites in Germany, Belgium, France
Ages 8–25
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: 0 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 4 · Phase 4 1
First in 2003; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 60 across 508 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 70 across the 24 interventional studies, 300 across the 14 observational. Of the 19 that completed or were terminated, 4 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 38 have an industry lead sponsor. The 10 most frequent:
Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.
Charite University, Berlin, Germany has 5 studies filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
4 of the studies in Heart Defects, Congenital with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06823635Fondation Hôpital Saint-JosephAn International Multicenter Study on Transcatheter Device Closure of Perimembranous Ventricular Septal Defects | 2026-12-31 |
| NCT07716488Alexandra Miriam KiessScreening for Disorders of Lipid Metabolism and Familial Hyperlipidemia in Children and Adolescents With Increased Cardiovascular Risk Due to Chronic Diseases Such as Congenital Heart Disease, Chronic Inflammatory Bowel Disease, Celiac Disease and Rheumatic Disorders | 2027-01-31 |
| NCT06845371University Hospital TuebingenMELODY Registry Follow-Up Study | 2027-05-01 |
| NCT07193719Charite University, Berlin, GermanyInfluence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies in Heart Defects, Congenital with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this randomized interventional clinical trial is to learn if a standardized lung volume optimization maneuver (LVOM) is beneficial in
The main questions it aims to answer are:
Main hypotheses of CHD study: Does a standardized PEEP-Titration maneuver, to optimize end-expiratory lung volume improve:
Does it make a difference in:
Main hypotheses of ECMO study:
Does a LVOM in children/infants with severe respiratory failure /ARDS
Does it make a difference in
1) The objective of the CHD study is to define the impact of a LVOM after cardiac surgery with CPB on hemodynamics and lung mechanics in children with congenital heart disease (CHD) undergoing surgery.
The Specific Aims of this work are:
Specific Aim 1:
Evaluate hemodynamics and lung mechanics during and after a LVOM:
In cases of children undergoing cardiac surgery all measurements will be performed with closed chest conditions.
Specific Aim 2:
Evaluate a potential benefit of lung volume optimization by performing PEEP titration on hemodynamics and lung mechanics compared to standard care without PEEP titration to optimize end-expiratory lung volume while maintaining same tidal volume targets in cases and controls.
Hypotheses:
Rationale: Surgery with cardiopulmonary bypass typically involves an interruption of mechanical ventilation while CPB is running. This is oftentimes associated with atelectasis formation and impaired gas exchange due to reduced end-expiratory lung volume. While there have been few studies in adults that have shown that optimization of lung volume by performing PEEP titration after CPB can significantly improve Cardiac Index and right ventricular function, there have been only very few prospective pediatric studies which assessed the impact of different PEEP settings on hemodynamics, and lung mechanics after cardiac surgery in children. Because these patients are generally among the most fragile postoperative patients, it is critical to understand if specific ventilator strategies can help mitigate any negative hemodynamic consequences after surgery. The purpose of this study is to understand the critical cardiopulmonary interactions that occur with changes in lung volumes, and to determine optimal approaches to mechanical ventilation under these different circumstances.
Cardiopulmonary interactions differ based on the underlying cardiac anatomy and physiology. Most studies of cardiopulmonary interactions following surgery for congenital heart disease have examined the difference between positive and negative pressure ventilation. This work consistently showed improvement in cardiac output and pulmonary blood flow with negative pressure ventilation, while positive pressure ventilation was associated with decreased cardiac output. However, these studies have been conducted in the 1990's and positive pressure ventilation has changed significantly in the meantime.
Similarly, while patients with left ventricular dysfunction generally benefit from positive pressure ventilation, there is little data regarding the hemodynamic effects of positive pressure ventilation on right ventricular performance.
Modulating pulmonary vascular resistance by optimizing lung volumes might be a promising approach to improve both lung mechanics and hemodynamics. Studies in this population have focused more on the effects of FiO2 and hyperventilation than on respiratory mechanics and cardiopulmonary interactions.
2) The objective of the ECMO study is to evaluate if a LVOM in children and infants with ARDS at risk or need for ECMO has an impact on ECMO prevention or shortening of ECMO duration.
Specific aims:
Rationale:
Children with NARDS or PARDS usually have reduced lung volumes. Typically ECMO is initiated when oxygenation index approaches 40 with further deterioration of hypercarbia, hemodynamics and worsening hypoxemia. Current treatment strategies include reducing ventilatory support on ECMO ("rest settings") which is typically followed by a "whiteout" of the lungs reflecting lung collapse and fluid infiltration. Usually within 10 days of ECMO support invasive ventilation is gradually increased to re-open the lung and allow for ECMO weaning. Optimizing lung volumes by performing a LVOM early on in the disease process might be beneficial to wean ECMO faster or even prevent its need by avoiding massive lung collapse during rest settings in patients that have high potential for lung recruitability.
CHD study:
Inclusion Criteria
Exclusion Criteria:
ECMO study Inclusion Criteria
Exclusion Criteria:
- severe lung hypoplasia or interstitial lung disease
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CHD study: This group receives so called standard of care. This includes relatively low levels of PEEP (5cmH2O in case of planned surgery) and no standardized PEEP titration ECMO study: This group receives so called standard of care. This includes PEEP of 10cmH2O, peak inspiratory pressures of 20cmH2O and no standardized PEEP titration
Procedure: Standard Care (in control arm)
CHD study: This group receives an individual lung volume optimization maneuver with PEEP titration. PEEP titration is performed while monitoring lung mechanics to optimize end-expiratory lung volume and find final "best PEEP". ECMO study: This group receives an individual lung volume optimization maneuver with PEEP titration during conventional or CDP titration with high frequency oscillatory ventilation. PEEP/CDP titration is performed while monitoring lung mechanics and EIT indices to optimize end-expiratory lung volume and find final "best PEEP/CDP".
Procedure: End-expiratory lung volume optimization maneuver with PEEP titration
CHD study: PEEP titration (incremental/decremental) will be performed to optimize lung volume and find levels of PEEP corresponding to the best lung compliance at the end of surgery. Typically PEEP levels between 10-20cmH2O will be applied based on individual response of patients' lung mechanics. Tidal volume will be kept constant at 6ml/kg in cases and controls. Driving pressures will be limited to 15cmH2O. Balance of CO2 will be guaranteed by adjusting respiratory rate. ECMo study: PEEP/CDP titration (incremental/decremental) will be performed to optimize lung volume and find levels of PEEP/CDP corresponding to the best lung compliance, best match of overdistension and collapse and homogenization of tidal volume distribution (EIT) .
CHD study: Patients will receive pressure controlled ventilation with target tidal volume of 6ml/kg and PEEP of 5cmH2O. Driving pressures are limited to 15cmH2O. No LVOM will be applied. ECMO study: patients will receive standard ECMO ventilation (PEEP 10cmH2O and PiP 20cmH2O) without performing LVOM
CHD study: Cardiac Index (L/min/BSA) 2. ECMO study: shortening of ECMO duration (Hours)
CHD study: assessed by using POCUS ECMO study: time course (Hours)
Time frame: perioperatively/periprocedurally
lung mechanics
lung compliance (ml/cmH2O/kg)
Time frame: perioperatively/periprocedurally
right ventricular performance
TAPSE PAAT Strain
Time frame: perioperatively/periprocedurally
Ventilation distribution
EIT
Time frame: perioperatively/periprocedurally
Lung perfusion
assessed with EIT (electrical impedance tomography)
Time frame: perioperatively/periprocedurally
dead space
pulmonary dead-space fraction (Vd/Vt)
Time frame: perioperatively/periprocedurally
avDO2
difference in arteriovenous oxygen content
Time frame: perioperatively/periprocedurally
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for May 2027, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charite University, Berlin, Germany →